[EN] RING FUSED, UREIDOARYL- AND CARBAMOYLARYL-BRIDGED MORPHOLINO-PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES [FR] COMPOSÉS DE MORPHOLINO-PYRIMIDINE À PONT URÉIDOARYLE ET CARBAMOYLARYLE, À CYCLES CONDENSÉS, LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE MTOR ET DE KINASE PI3, ET LEURS SYNTHÈSES
[EN] RING FUSED, UREIDOARYL- AND CARBAMOYLARYL-BRIDGED MORPHOLINO-PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES [FR] COMPOSÉS DE MORPHOLINO-PYRIMIDINE À PONT URÉIDOARYLE ET CARBAMOYLARYLE, À CYCLES CONDENSÉS, LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASE MTOR ET DE KINASE PI3, ET LEURS SYNTHÈSES
The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
FUSED HETEROARYL DERIVATIVES
申请人:HAYAKAWA Masahiko
公开号:US20100137584A1
公开(公告)日:2010-06-03
The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.